FENC vs. KOD, IPSC, ELEV, INMB, OPT, IPHA, ADVM, GNFT, CGEN, and ABOS
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Kodiak Sciences (KOD), Century Therapeutics (IPSC), Elevation Oncology (ELEV), INmune Bio (INMB), Opthea (OPT), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), Genfit (GNFT), Compugen (CGEN), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "biological products, except diagnostic" industry.
Kodiak Sciences (NASDAQ:KOD) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Comparatively, 11.3% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Kodiak Sciences presently has a consensus price target of $5.50, suggesting a potential upside of 47.06%. Fennec Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 129.23%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Kodiak Sciences.
Fennec Pharmaceuticals has higher revenue and earnings than Kodiak Sciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Fennec Pharmaceuticals received 175 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 65.65% of users gave Fennec Pharmaceuticals an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Kodiak Sciences has a net margin of 0.00% compared to Kodiak Sciences' net margin of -75.50%. Kodiak Sciences' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.
In the previous week, Fennec Pharmaceuticals had 8 more articles in the media than Kodiak Sciences. MarketBeat recorded 13 mentions for Fennec Pharmaceuticals and 5 mentions for Kodiak Sciences. Fennec Pharmaceuticals' average media sentiment score of 0.47 beat Kodiak Sciences' score of 0.42 indicating that Kodiak Sciences is being referred to more favorably in the media.
Summary
Fennec Pharmaceuticals beats Kodiak Sciences on 10 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
